Lanadelumab
id:
lanadelumab-228-3620130
title:
Lanadelumab
text:
Lanadelumab, sold under the brand name Takhzyro, is a human monoclonal antibody that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in people with hereditary angioedema. Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema attacks. Lanadelumab is the first treatment for hereditary angioedema prevention made by using cells within a lab, not human plasma. Common side effe
brand slug:
wiki
category slug:
encyclopedia
description:
Monoclonal antibody
original url:
https://en.wikipedia.org/wiki/Lanadelumab
date created:
2016-07-02T13:49:23Z
date modified:
2024-09-15T05:07:14Z
main entity:
{"identifier":"Q25326708","url":"https://www.wikidata.org/entity/Q25326708"}
image:
fields total:
13
integrity:
15